Sep 26, 2026
C4 Therapeutics Presents New Biomarker Data from the Cemsidomide Phase 1 Trial with Dexamethasone and Phase 1b Trial with Elranatamab in Relapsed/Refractory Multiple Myeloma at the 23rd International Myeloma Society Annual Meeting
C4 Therapeutics (Nasdaq: CCCC) presented new biomarker data from its Phase 1 trial of cemsidomide with dexamethasone and preliminary data from its Phase 1b trial with elranatamab for relapsed/refractory multiple myeloma at the 23rd IMS Annual Meeting. The data highlights cemsidomide's immunomodulatory effects, including T-cell activation and prevention of T-cell exhaustion, suggesting its potential to enhance immune-based therapies. The 75 µg cemsidomide dose level in the Phase 1b trial was declared safe, allowing advancement to dose escalation and expansion cohorts, with further data expected mid-2027.
Company relevance
100.00%
Company sentiment
Bullish
Overall sentiment
Bullish
Sep 22, 2026
C4 Therapeutics CFO Kendra Adams Reports RSU Vesting and Tax Withholding Transactions
C4 Therapeutics CFO Kendra Adams recently reported two stock transactions involving RSU vesting and tax withholding. On September 18, 2026, Adams acquired 6,250 common shares from vested restricted stock units and had 2,775 shares withheld at $3.39 each to cover tax liabilities. Following these transactions, Adams directly holds 382,323 shares of C4 Therapeutics common stock.
Company relevance
100.00%
Company sentiment
Neutral
Overall sentiment
Neutral